Curis’ CA-4948 is a first-in-class IRAK4 inhibitor that is in clinical development for AML/MDS and NHL. It’s estimated that over 50% of AML patients have the IRAK4-L isoform, providing a nice patient population that could be eligible for this therapy. The company provided a recent update in anticipation of the European Hematology Association meeting in early June. They showed 8 out of 9 patients receiving some benefit from the treatment with 4 patients having a strong response (CR or CRi).
In this video, I go through the company’s clinical programs and evaluate what we can look forward to next. I also touch on $ANVS and $SIOX.
Presentation slides: https://drive.google.com/drive/folders/1MENe3kFzFosR6-ALPoY9ovpXXcERH_j3?usp=sharing
Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech
Follow me on twitter @matthewlepoire
Send me an email firstname.lastname@example.org http://www.breakingbiotech.com #breakingbiotech
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech